Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/3/2025

Insulin Administration Guidelines for Hospitalized Patients with Hyperglycemia

Rationale for Administration

  • The American Diabetes Association recommends basal insulin (Lantus/insulin glargine) plus correction insulin (Lispro/insulin lispro) as the preferred treatment for hospitalized patients with hyperglycemia, especially when blood glucose levels are elevated above target range 1, 2
  • A blood glucose level of 279 mg/dL indicates significant hyperglycemia that requires treatment to prevent further metabolic derangement, with a strength of evidence rating of B 3
  • Using only sliding scale insulin without basal insulin (Lantus) is strongly discouraged in hospital settings as it leads to poor glycemic control, with a high level of evidence 2, 4

Insulin Administration

  • For hospitalized patients with hyperglycemia, a regimen with both basal insulin (Lantus) and correction components (Lispro) is the standard of care, as recommended by the American Association of Clinical Endocrinologists 1, 2
  • Lantus (insulin glargine) provides essential background insulin coverage for 24 hours, with a moderate level of evidence 3
  • For patients not eating, glucose monitoring every 4-6 hours with appropriate insulin administration is recommended, with a low level of evidence 4, 5

Monitoring and Prevention

  • After administering insulin, continue to monitor the patient for potential hypoglycemia, especially during nighttime hours, with a high level of evidence 6
  • Document the administration and subsequent blood glucose readings in the medical record, as recommended by the American Diabetes Association 2
  • Ensure the scheduled blood glucose check is performed to evaluate the effectiveness of the insulin administration, with a moderate level of evidence 5
  • Verify that the patient has no contraindications to receiving the prescribed insulin doses, with a high level of evidence 1

Hypoglycemia Prevention

  • Be aware of the risk of hypoglycemia, particularly during overnight hours, with a high level of evidence 6
  • Have hypoglycemia treatment protocols readily available, with a moderate level of evidence 2
  • If hypoglycemia occurs after administration, follow the institution's hypoglycemia management protocol and document the episode, with a high level of evidence 6
  • Consider reviewing the insulin regimen if repeated hypoglycemic episodes occur, with a moderate level of evidence 2

Common Pitfalls to Avoid

  • Withholding basal insulin (Lantus) when blood glucose is elevated is a common error that leads to worsening hyperglycemia, with a high level of evidence 1, 7
  • Using only sliding scale insulin (Lispro) without basal insulin leads to poor glycemic control and glucose variability, with a high level of evidence 2, 7
  • Delaying insulin administration when indicated can lead to worsening hyperglycemia and metabolic complications, with a moderate level of evidence 3
  • Failing to monitor blood glucose after insulin administration increases the risk of undetected hypoglycemia, with a high level of evidence 2

Management of Sliding Scale Insulin in Patients Receiving Mealtime Insulin

  • The American Diabetes Association recommends a basal-bolus insulin regimen as the preferred treatment for hospitalized patients with hyperglycemia, rather than sliding scale insulin alone 8, 9
  • This regimen consists of basal insulin and prandial insulin administered before meals, with correction insulin as needed for hyperglycemia, as recommended by the American Diabetes Association 9

Evidence Against Sliding Scale Insulin

  • The American Diabetes Association strongly discourages the prolonged use of sliding scale insulin as the sole treatment of hyperglycemic inpatients, due to poor glycemic control and increased risk of complications 8, 9
  • Randomized controlled trials have shown that basal-bolus treatment improved glycemic control and reduced hospital complications compared to reactive sliding scale insulin regimens, with a moderate to high strength of evidence 9

When to Use Correction Insulin

  • For patients already receiving scheduled mealtime insulin, a simplified correction scale may be used temporarily while adjusting prandial insulin doses, as recommended by the American Diabetes Association 10
  • A correction scale with 2 units of short- or rapid-acting insulin for premeal glucose >250 mg/dL (>13.9 mmol/L) and 4 units for premeal glucose >350 mg/dL (>19.4 mmol/L) may be used, with a low to moderate strength of evidence 10

Common Pitfalls to Avoid

  • Failing to transition from sliding scale to a more physiologic insulin regimen can lead to prolonged hyperglycemia, as warned by the American Diabetes Association 8, 9
  • Premixed insulin formulations are not routinely recommended for in-hospital use due to increased hypoglycemia risk, with a high strength of evidence 9
  • Implement a basal-bolus insulin regimen with basal insulin (glargine, detemir, or degludec) once daily, prandial insulin (lispro, aspart, or glulisine) before meals, and correction insulin only as needed for significant hyperglycemia, as recommended by the American Diabetes Association 9, 10
  • Insulin injections should align with meals, with point-of-care glucose testing performed immediately before meals, with a moderate strength of evidence 9
  • Discontinue sliding scale insulin once the patient is stabilized on an appropriate basal-bolus regimen, as recommended by the American Diabetes Association 10

Management of Hyperglycemia in Hospitalized Patients

Introduction to Basal-Bolus Insulin Regimen

  • The American Diabetes Association recommends against using sliding scale insulin as the sole method of treatment in hospitalized patients, as it is inadequate for achieving good glycemic control 11
  • A bedtime glucose level of 221 mg/dL exceeds the recommended target of <180 mg/dL for hospitalized patients, and is associated with increased infection risk and higher in-hospital mortality and complications 12, 13

Importance of Basal-Bolus Regimen

  • Randomized trials demonstrate that basal-bolus regimens provide superior glycemic control and reduce hospital complications compared to sliding scale insulin alone, although the specific citation for this fact is not provided, the American Diabetes Association supports the use of basal-bolus regimens 11

Monitoring and Titration

  • The American Diabetes Association recommends monitoring for hypoglycemia, especially overnight between midnight and 6:00 AM when risk peaks, and adjusting the insulin regimen accordingly 14
  • If glucose falls <100 mg/dL, reassess the regimen, and if glucose <70 mg/dL, reduce insulin dose by 10-20% immediately 12, 14

Glycemic Control Targets

  • Target fasting glucose should be between 80-130 mg/dL, and basal insulin should be increased aggressively based on fasting glucose patterns, with a goal of achieving good glycemic control 12

Bedtime Hyperglycemia Correction in Hospitalized Patients

Immediate Management

  • A bedtime glucose of 12.3 mmol/L (221 mg/dL) exceeds the recommended target of <10.0 mmol/L (<180 mg/dL) for hospitalized patients and indicates inadequate glycemic control, according to the American Diabetes Association 15

Transition to Appropriate Insulin Regimen

  • Target glucose range of 7.8-10.0 mmol/L (140-180 mg/dL) for most hospitalized patients, as recommended by the American Diabetes Association 15
  • More stringent targets of 6.1-7.8 mmol/L (110-140 mg/dL) may be appropriate for selected patients if achievable without significant hypoglycemia, according to the American Diabetes Association 15

Monitoring Requirements

  • Point-of-care glucose testing should be performed before meals for patients eating, or every 4-6 hours for patients not eating, as recommended by the American Diabetes Association 15

REFERENCES

← Return to Home